Eagle Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Eagle Pharmaceuticals

09/05/2023 14:32

* Eagle Pharmaceuticals Inc  EGRX.OQ  reported quarterly
adjusted
earnings of $1.26​​ per share for the quarter ended in March.
The mean expectation of three analysts for the quarter was
for earnings of $1.05 per share.
    * Revenue fell 42.8% to $66.31 million from a year ago;
analysts
expected $63.29 million. 
    * Eagle Pharmaceuticals Inc's reported EPS for the quarter
was 44
cents​.
    * The mean earnings estimate of analysts had risen by
about 13.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eagle Pharmaceuticals Inc shares had risen by 2.8% this
quarter and lost 0.2% so far this year.
    * The company reported quarterly net income of $5.75
million.
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      1.05           1.26           Beat
 Dec. 31 2022      0.83           1.10           Beat
 Sep. 30 2022      0.91           1.12           Beat
 Jun. 30 2022      3.36           1.56           Missed